News

Technology News

Aclaris Thera Clears $40 Million Series C Funding

Monday, September 14, 2015 5:03:00 AM PDT | VentureDeal

Malvern, Pennsylvania -- Aclaris Therapeutics has secured $40 million in its third round of institutional venture capital investment, according to an SEC regulatory filing.

Aclaris is a pharmaceutical company that is developing novel topical dermatological therapies applied directly toward the removal of seborrheic keratosis and other verrucoid lesions of the skin.

The company was founded in July 2012.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Aclaris is backed by a syndicate of venture capital firms including Fidelity BioSciences.

Email Page | Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

About VentureDeal

Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.

Learn More »

Home
Overview
Service Firms
Tech Entrepreneurs
Venture Investors

Services
Subscribe
Use Cases

FAQ
Terms of Use
Privacy Policy
Contact
Login